Amgen Inc. (AMGN) FY2024 Q3 P&L / Income Statement
2024-07-01 to 2024-09-30
Revenue by Product and Service by Geography
2024-07-01 to 2024-09-30
Swipe to see the full flow
Chart details
Amgen Inc. (AMGN) FY2024 Q3 P&L / Income Statement
Income statement for 2024-07-01 through 2024-09-30. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.
- Total revenues
- 8,503,000,000 US dollars
- Cost of sales
- 3,310,000,000 US dollars
- Gross profit (calculated)
- 5,193,000,000 US dollars
- Operating expenses (calculated)
- 3,146,000,000 US dollars
- Operating income
- 2,047,000,000 US dollars
- Other income (expense), net (calculated)
- 1,054,000,000 US dollars
- Income before income taxes
- 3,101,000,000 US dollars
- Provision for income taxes
- 271,000,000 US dollars
- Net income
- 2,830,000,000 US dollars
- Aranesp - UNITED STATES
- 105,000,000 US dollars
- Aranesp - Non-US
- 232,000,000 US dollars
- BLINCYTO - UNITED STATES
- 237,000,000 US dollars
- BLINCYTO - Non-US
- 90,000,000 US dollars
- EVENITY - UNITED STATES
- 289,000,000 US dollars
- EVENITY - Non-US
- 110,000,000 US dollars
- ENBREL - UNITED STATES
- 817,000,000 US dollars
- ENBREL - Non-US
- 8,000,000 US dollars
- KRYSTEXXA - UNITED STATES
- 310,000,000 US dollars
- KRYSTEXXA - Non-US
- 0 US dollars
- Kyprolis - UNITED STATES
- 238,000,000 US dollars
- Kyprolis - Non-US
- 140,000,000 US dollars
- Nplate - UNITED STATES
- 345,000,000 US dollars
- Nplate - Non-US
- 111,000,000 US dollars
- Otezla - UNITED STATES
- 460,000,000 US dollars
- Otezla - Non-US
- 104,000,000 US dollars
- Other products - UNITED STATES
- 958,000,000 US dollars
- Other products - Non-US
- 405,000,000 US dollars
- Prolia - UNITED STATES
- 683,000,000 US dollars
- Prolia - Non-US
- 362,000,000 US dollars
- Repatha - UNITED STATES
- 281,000,000 US dollars
- Repatha - Non-US
- 286,000,000 US dollars
- TEPEZZA - UNITED STATES
- 482,000,000 US dollars
- TEPEZZA - Non-US
- 6,000,000 US dollars
- TEZSPIRE - UNITED STATES
- 269,000,000 US dollars
- TEZSPIRE - Non-US
- 0 US dollars
- Vectibix - UNITED STATES
- 132,000,000 US dollars
- Vectibix - Non-US
- 150,000,000 US dollars
- XGEVA - UNITED STATES
- 373,000,000 US dollars
- XGEVA - Non-US
- 168,000,000 US dollars
- Product sales - UNITED STATES
- 5,979,000,000 US dollars
- Product sales - Non-US
- 2,172,000,000 US dollars
- Research and development
- 1,450,000,000 US dollars
- Selling, general and administrative
- 1,625,000,000 US dollars
- Other
- 71,000,000 US dollars
- Revenue before reconciliation (calculated)
- 16,302,000,000 US dollars. Sum of the reported revenue categories before the separately reported reconciliation.
- Components above reported revenue (calculated)
- negative 7,799,000,000 US dollars. The disclosed components add up to more than reported revenue; this is the difference, calculated, not a reported item.
Chart connections
- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Reported revenue categories plus the separately reported signed reconciliation equals consolidated revenue.
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG
Gross margin
61.1%
Gross profit / revenue
Operating margin
24.1%
Operating profit / revenue
Cash conversion
126.2%
Operating cash / net income, same period
Product waitlist
Health Check and Teardown for your own company
A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!